KING TRIAL

  1. WHERE WAS THE KING STUDY PUBLISHED AND WHEN
    2009 DIABETES OBES METABOLISM
  2. WHAT WAS THE STUDY DESIGN OF THE KING STUDY?
    RANDOMIZED, DOUBLE BLIND, CROSSOVER
  3. PRIMARY OBJECTIVE OF THE KING STUDY?
    TO EVALUTATE IF LEVEMIR AND INSULIN GLARGINE USED ONCE A DAY YIELD SIMILAR 24HR GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES USING CGSM.
  4. HOW MANY PATIENTS WERE IN THE KING STUDY?
    36 PATIENTS
  5. WHEN WERE THE PATIENTS GIVEN THE INSULIN INJECTION IN THE KING STUDY?
    QD INJECTION AT 8PM EITHER LEVEMIR OR GLARGINE
  6. WHEN WERE THE INSULIN DOSE SWITHCED TO THE OTHER INSULIN IN THE KING STUDY?
    AFTER PATIENT ACHIEVED 2 CONSECUTIVE DAYS AT GOAL, THEY WERE SWITCHED AND PROCESS WAS REPEATED.
  7. WHAT WAS THE PRIMARY END POINT IN THE KING STUDY?
    COMPARISION OF THE MEAN GLUCOSE VALUES ACHIEVED DURING THE BASAL PERIOD (12AM TO 6AM) BETWEEN LEVEMIR AND GLARGINE.
  8. EXCLUSION CRITERIA FROM THE KING STUDY
    PRIOR TREATMENT WITH BOLUS INSULIN
  9. WHEN WAS THE LAST MEAL IN THE KING STUDY FOR PATIENTS?
    6PM
  10. AVERAGE AGE IN THE KING STUDY AND BMI?
    58.9 YEARS AND 34.9 BMI
  11. HOW MANY DAY DID IT TAKE IN THE LEVEMIR ARM IN THE KING STUDY TO REACH GLYCEMIC CONTROL AND GLARGINE ARM?
    LEVEMIR ARM 3.8 DAYS

    GLARGINE ARM 3.5 DAYS
  12. WHAT WAS THE MEAN DOSE OF INSULIN IN BOTH ARMS IN THE KING STUDY?
    26.3 UNITS LEVEMIR

    26.6 UNITS FOR GLARGINE
Author
Susanslcm
ID
45217
Card Set
KING TRIAL
Description
ONCE DAILY INSULIN DETEMIR IS COMPARABLE TO ONCE DAILY INSULIN GLARGINE IN PROVIDING GLYCAEMIC CONTROL OVER 24HRS IN PATIENTS WITH TYPE 2 DIABETES: A DOUBLE-BLIND, RANDOMIZED, CROSSOVER STUDY.
Updated